Compare DG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | ROIV |
|---|---|---|
| Founded | 1939 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2B | 25.1B |
| IPO Year | 2008 | 2021 |
| Metric | DG | ROIV |
|---|---|---|
| Price | $130.97 | $34.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | ★ $139.60 | $28.94 |
| AVG Volume (30 Days) | 2.0M | ★ 7.1M |
| Earning Date | 06-02-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ 34.05 | N/A |
| EPS | ★ 4.49 | N/A |
| Revenue | ★ $42,724,369,000.00 | $8,260,000.00 |
| Revenue This Year | $7.14 | N/A |
| Revenue Next Year | $4.17 | $744.61 |
| P/E Ratio | $29.16 | ★ N/A |
| Revenue Growth | ★ 5.20 | N/A |
| 52 Week Low | $95.11 | $12.54 |
| 52 Week High | $158.23 | $37.97 |
| Indicator | DG | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 62.88 | 41.14 |
| Support Level | $115.31 | $33.01 |
| Resistance Level | $132.31 | $37.59 |
| Average True Range (ATR) | 3.86 | 1.19 |
| MACD | 0.85 | -0.38 |
| Stochastic Oscillator | 83.84 | 15.53 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.